2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16638
    CB 3717 76849-19-9 98%
    CB 3717 is a potent inhibitor of human thymidylate synthetase, competitively binding with 5,10-methylenetetrahydrofolate (Ki = 4.9 X 10(-9) M). It also competitively inhibits human dihydrofolate reductase with dihydrofolate (Ki = 2.3 X 10(-8) M). In WI-L2 human lymphoblastoid cells, CB 3717 treatment led to a significant decrease in cellular dTTP levels and a notable increase in dUMP levels, indicating a disruption in nucleotide metabolism. The growth-inhibitory effect of CB 3717 was reversed by thymidine supplementation, demonstrating that thymidylate synthetase became rate-limiting in the presence of this compound. Delayed thymidine supplementation beyond 8 hours resulted in severe cytotoxicity, underscoring the critical timing of nucleotide rescue strategies in CB 3717-treated cells.
    CB 3717
  • HY-16656
    BMS-767778 915729-95-2 98%
    BMS-767778 is an orally active and selective DPP4 inhibitor with Ki values of 0.94 nM, 4.9, 3.2 nM for DPP4, DPP8 and DPP9 respectively. BMS-767778 exhibits >3,000-fold selectivity over the related enzymes DPP8 and DPP9. BMS-767778 inhibits CYP-3A4 with IC50 of 5.2 μM. BMS-767778 significantly reduces blood glucose levels in high fat fed (HFD) ob/ob mice with safety profile. BMS-767778 can be used for diabetes mellitus research.
    BMS-767778
  • HY-16729
    Relenopride 1221416-43-8 98%
    Relenopride is a agonist of novel potent 5-HT4 receptor partial with weak binding to 5-HT 2B receptors (Ki = 31 nM).
    Relenopride
  • HY-16778
    Etiguanfacine 1346686-31-4 98%
    Etiguanfacine is a derivative of Guanfacine (HY-17416A). Etiguanfacine can be used for research to reduce the gastrointestinal side effects of Guanfacine.
    Etiguanfacine
  • HY-16946
    CP-610431 591778-83-5 98%
    CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC50s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome.
    CP-610431
  • HY-17011
    Croconazole 77175-51-0 99.24%
    Croconazole is an antifungal agent containing imidazole rings. Croconazole has a unique structural feature of aryl vinyl at the imidazole ring N-1. Croconazole can be used for the identification and quantitative study of major metabolites in rat urine and bile .
    Croconazole
  • HY-17666
    (-)-Adenophorine 616215-43-1
    (-)-Adenophorine (Compound 7c) is a glycosidase inhibitor. (-)-Adenophorine inhibits α-L-fucosidase with an IC50 of 72 μM.
    (-)-Adenophorine
  • HY-18344
    Satavaptan 185913-78-4 98%
    Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia.
    Satavaptan
  • HY-18354
    GSK1104252A 1001397-20-1 98%
    GSK1104252A is a potent and selective GPR119 agonist. GSK1104252A can be used for type 2 diabetes research.
    GSK1104252A
  • HY-18612
    MK-7725 1034152-93-6 98%
    MK-7725 is a selective, orally active, and blood-brain barrier-permeable agonist of the subtype 3 of the frog skin peptide receptor (BRS-3). MK-7725 has a high affinity for the human BRS-3 (hBRS-3), with an IC50 of 3 nM, and its functional activity in the mouse-derived BRS-3 (mBRS-3) model with an EC50 of 22 nM (105% agonistic). MK-7725 significantly reduces the body weight of obese rats and obese dogs. MK-7725 can be used for the treatment of obesity.
    MK-7725
  • HY-19002
    BRL-26830A 87857-42-9 98%
    BRL-26830A is a β-adrenergic receptor agonist. BRL-26830A reduces body weight and increases metabolic rate in obese mouse models. BRL-26830A stimulates insulin release and significantly reduces blood glucose levels in ICR mouse models. BRL-26830A can be used to study endocrine and metabolic diseases such as obesity and diabetes.
    BRL-26830A
  • HY-19022
    BW A256C 98410-36-7 98%
    Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties.
    BW A256C
  • HY-19037
    SM-2470 99899-45-3 98%
    SM-2470 is a potent α1-adrenoceptor antagonist, has sympathetic nerve activity in anesthetized rats. SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization.
    SM-2470
  • HY-19077
    BMS-180431 129829-03-4 98%
    BMS-180431 is an inhibitor of HMG-CoA reductase (IC50: 43 nM).
    BMS-180431
  • HY-19107
    SQ-33600 133983-25-2 98%
    SQ-33600 is an HMG-CoA reductase inhibitor. SQ-33600 has cholesterol-lowering activity. SQ-33600 possesses cell-type selectivity, with much higher inhibitory activity on rat hepatocytes (IC50: 93 nM) than on human skin fibroblasts (IC50: 14200 nM). SQ-33600 can be used in the research of diseases such as hypercholesterolemia.
    SQ-33600
  • HY-19112
    447C88 130400-16-7 98%
    447C88 is an acyl-coenzyme A cholesterol acyltransferase (ACAT) inhibitor with an IC50 of 23 nM. 447C88 can reduce plasma cholesterol levels and can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.
    447C88
  • HY-19116
    KRN-2391 134431-49-5 98%
    KRN-2391 is a KATP channel opener with NO donor properties. KRN-2391 exerts dual inhibitory effects on overactive bladder (OAB) by activating KATP channels (causing cellular hyperpolarization and bladder smooth muscle relaxation) and releasing NO (enhancing relaxation via cGMP pathways). KRN-2391 is promising for research of OAB.
    KRN-2391
  • HY-19122
    JO-1870 hydrochloride 141034-43-7 98%
    JO-1870 hydrochloride is a selective opioid receptor agonist. JO-1870 hydrochloride exerts bladder relaxation via activation of opioid receptors. JO-1870 hydrochloride is promising for research of urinary incontinence.
    JO-1870 hydrochloride
  • HY-19133
    ME 3407 133903-90-9 98%
    ME-3407 (EF-4040) is a H+-K+-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H+-K+-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer.
    ME 3407
  • HY-19140
    YM-17E hydrochloride 124884-99-7 98%
    YM17E hydrochloride is an acyl CoA:cholesterol acyltransferase (ACAT) inhibitor, with IC50 of 44 nM. YM17E hydrochloride has hypocholesterolemic effect.
    YM-17E hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity